Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και Εκτέλεση
Library of the School of Health Sciences

2021-04-26

2021

Koustenis Kanellos-Rafail

Φλώρα Ζαγουρή, Αναπληρώτρια Καθηγήτρια , Ιατρική Σχολή, ΕΚΠΑ (Επιβλέπουσα)
Ευστάθιος Καστρίτης , Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Θεόδωρος Σεργεντάνης, Εκλεγμένος Επίκουρος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Νεότερες-στοχευμένες από του στόματος θεραπείες για τις Ιδιοπαθείς Φλεγμονώδεις Νόσους του Εντέρου και μελλοντικές προοπτικές

Greek

Emerging oral-targeted therapies for Inflammatory Bowel Disease and future prospects

Inflammatory bowel disease (IBD), including Crohn's disease (NC) and Ulcerative colitis (UC), is a chronic autoimmune disorder of the gastrointestinal tract with varying degrees of clinical manifestations. In the past, their treatment was based solely on the administration of aminosalicylates, corticosteroids and immunomodulatory drugs. In the last two decades, with the application of biological agents, it has been achieved the modification of the natural history of the disease. However, a large proportion of patients do not respond to these therapies and in combination with their high cost and potential side effects, there is particular interest in developing small, targeted and effective oral molecular drugs. The purpose of this review is to list the different molecular pathways through which these drugs act and the most important findings from Phase II and III clinical trials. Among these, Janus kinase inhibitors (JAK) and sphingosine receptor modulators (S1P) are at a more advanced stage of development. Tofacitinib (JAK inhibitor) has recently been approved for the treatment of moderate to severe UC and other JAK inhibitors (filgotinib, upadacitinib) have shown satisfactory results from phase II studies. Furthermore, safety and efficacy data have been obtained for ozanimod and etrasimod (S1P receptor modulators), AJM-300 (integrin receptor antagonist), LT-02 (modified release phosphatidylcholine) and Morgensen (SMAD7 inhibitor) with some of them being tested in phase III clinical trials. At the same time, several other oral agents are still in development. Therefore, it is expected that the therapeutic choices for IBD will soon be enriched with targeted, oral molecular therapies, in addition to parenterally administered biological therapies, with the ultimate goal being the remission of the disease and the improvement of patients’ quality of life.

Health Sciences

IBD, Small molecules, Oral

No

0

Yes

53

48

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2943404